255 related articles for article (PubMed ID: 2467993)
1. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
Baxt B; Vakharia V; Moore DM; Franke AJ; Morgan DO
J Virol; 1989 May; 63(5):2143-51. PubMed ID: 2467993
[TBL] [Abstract][Full Text] [Related]
2. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.
Saiz JC; Gonzalez MJ; Borca MV; Sobrino F; Moore DM
J Virol; 1991 May; 65(5):2518-24. PubMed ID: 1707983
[TBL] [Abstract][Full Text] [Related]
3. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants.
Butchaiah G; Morgan DO
Virus Res; 1997 Dec; 52(2):183-94. PubMed ID: 9495534
[TBL] [Abstract][Full Text] [Related]
4. Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus.
Moore DM; Vakharia VN; Morgan DO
Virus Res; 1989 Dec; 14(4):281-95. PubMed ID: 2483013
[TBL] [Abstract][Full Text] [Related]
5. Antigenic sites on foot-and-mouth disease virus type A10.
Thomas AA; Woortmeijer RJ; Puijk W; Barteling SJ
J Virol; 1988 Aug; 62(8):2782-9. PubMed ID: 2455819
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
[TBL] [Abstract][Full Text] [Related]
8. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
Stave JW; Card JL; Morgan DO
J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
[TBL] [Abstract][Full Text] [Related]
9. Host cell selection of antigenic variants of foot-and-mouth disease virus.
Bolwell C; Brown AL; Barnett PV; Campbell RO; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
J Gen Virol; 1989 Jan; 70 ( Pt 1)():45-57. PubMed ID: 2471782
[TBL] [Abstract][Full Text] [Related]
10. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
Stave JW; Card JL; Morgan DO; Vakharia VN
Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
[TBL] [Abstract][Full Text] [Related]
11. The main antigenic determinant detected by neutralizing monoclonal antibodies on the intact foot-and-mouth disease virus particle is absent from isolated VPI.
Meloen RH; Briaire J; Woortmeyer RJ; van Zaane D
J Gen Virol; 1983 May; 64(Pt 5):1193-8. PubMed ID: 6188800
[TBL] [Abstract][Full Text] [Related]
12. Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12.
Robertson BH; Morgan DO; Moore DM
Virus Res; 1984 Sep; 1(6):489-500. PubMed ID: 6085200
[TBL] [Abstract][Full Text] [Related]
13. Evidence for more than one important, neutralizing site on foot-and-mouth disease virus. Brief report.
Thomas AA; Woortmeijer RJ; Barteling SJ; Meloen RH
Arch Virol; 1988; 99(3-4):237-42. PubMed ID: 2453185
[TBL] [Abstract][Full Text] [Related]
14. Analysis of neutralizing epitopes on foot-and-mouth disease virus.
Pfaff E; Thiel HJ; Beck E; Strohmaier K; Schaller H
J Virol; 1988 Jun; 62(6):2033-40. PubMed ID: 2835507
[TBL] [Abstract][Full Text] [Related]
15. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies.
Bolwell C; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
J Gen Virol; 1989 Jan; 70 ( Pt 1)():59-68. PubMed ID: 2471783
[TBL] [Abstract][Full Text] [Related]
16. Foot-and-mouth disease and its antigens.
Bachrach HL
Adv Exp Med Biol; 1985; 185():27-46. PubMed ID: 2416203
[TBL] [Abstract][Full Text] [Related]
17. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C.
Mateu MG; MartÃnez MA; Capucci L; Andreu D; Giralt E; Sobrino F; Brocchi E; Domingo E
J Gen Virol; 1990 Mar; 71 ( Pt 3)():629-37. PubMed ID: 1690261
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.
Barnett PV; Samuel AR; Pullen L; Ansell D; Butcher RN; Parkhouse RM
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1687-97. PubMed ID: 9680132
[TBL] [Abstract][Full Text] [Related]
19. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants.
Crowther JR; Farias S; Carpenter WC; Samuel AR
J Gen Virol; 1993 Aug; 74 ( Pt 8)():1547-53. PubMed ID: 8393912
[TBL] [Abstract][Full Text] [Related]
20. Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus.
Meloen RH; Puyk WC; Meijer DJ; Lankhof H; Posthumus WP; Schaaper WM
J Gen Virol; 1987 Feb; 68 ( Pt 2)():305-14. PubMed ID: 2434606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
